Brad H. Rovin

The Ohio State University Wexner Medical Center — United States

Medicine · Health Sciences

91h-index37.7kcitations707works9.92yr avg

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Renal Diseases and Glomerulopathies(309), Systemic Lupus Erythematosus Research(271), Chronic Kidney Disease and Diabetes(95), Liver Diseases and Immunity(54), Vasculitis and related conditions(50)

Publications678 total

Renal Replacement Therapy in Lupus Nephritis–Related End‐Stage Kidney Disease: A Systematic Review and Meta‐Analysis

ACR Open Rheumatology·2025Open Access

Corrigendum to “Treatment of patients with IgA nephropathy: a call for a new paradigm.” Kidney International 2025;107:640–651

Kidney International·2025Open Access

A Pooled Analysis of Sex Differences in Lupus Nephritis

Kidney International Reports·2025Open Access

Iptacopan in Patients With IgA Nephropathy From East Asia

Kidney International Reports·2025Open Access

A Qualitative Analysis of Patient Perspectives and Preferences in Lupus Management to Guide Lupus Guidelines Development

1 cited

Arthritis Care & Research·2025· 1 citedOpen Access

Inflammatory dendritic cell drives intra-renal T cells to double-negative T cells in lupus nephritis 4065

The Journal of Immunology·2025Open Access

Biomarkers of Lupus Nephritis Histopathology: Where Do We Stand?

Arthritis & Rheumatology·2025Open Access

#3596 Biomarkers of lupus nephritis histopathology: Where do we stand?

Nephrology Dialysis Transplantation·2025Open Access

Combined Transcriptomics and Proteomics Approach to Identify Immune Signatures in ANCA-Associated Glomerulonephritis

Journal of the American Society of Nephrology·2025

Expert Consensus on the Likelihood and Treatment of Inflammatory and Fibrotic IgAN

Journal of the American Society of Nephrology·2025

#2651 Sustainability and depth of UPCR reduction in patients with primary IgAN treated with nefecon: a secondary analysis of the Phase 3 NefIgArd trial

Nephrology Dialysis Transplantation·2025Open Access

#248 Effects of obinutuzumab on urinary renal biomarkers in lupus nephritis: a <i>post hoc</i> exploratory analysis of the phase II nobility study

Nephrology Dialysis Transplantation·2025Open Access

#3251 Nefecon provides kidney benefit irrespective of time since diagnosis in patients with IgAN: a subanalysis of the NefIgArd study

Nephrology Dialysis Transplantation·2025Open Access

Absolute Proteinuria over Time with Nefecon vs. Placebo in Patients with IgAN: Results from the Phase 3 NefIgArd Trial

Journal of the American Society of Nephrology·2025

Beyond Clinical Response in the REGENCY Trial: The Impact of Obinutuzumab on Histologic Remission in Patients with Active Lupus Nephritis

Journal of the American Society of Nephrology·2025

MG53 in Sepsis-Induced AKI: Underlying Mechanisms for Renoprotection

Journal of the American Society of Nephrology·2025

Urinary Tenascin C Predicts Kidney Function Loss in Lupus Nephritis

Journal of the American Society of Nephrology·2025

Kidney Function Preservation with Belimumab in Patients with Lupus Nephritis Receiving Mycophenolate Mofetil (MMF) Standard Therapy in the BLISS-LN Trial: Improved Proteinuria, Clinical Outcomes, and Biomarkers for Belimumab vs. Placebo

Journal of the American Society of Nephrology·2025

Evaluation of Long-Term Disease Modification with Belimumab (BEL) in Routine Care of Patients (Pts) with Lupus Nephritis (LN): The OBSErve-LN Study

Journal of the American Society of Nephrology·2025

Profiling a Large Cohort of Patients with Lupus Nephritis Managed at a Safety-Net Hospital in Mexico City

Journal of the American Society of Nephrology·2025

page 1 of 34Next →

Frequent Co-authors

Jonathan Barratt(11), Jürgen Floege(10), Fernando C. Fervenza(9), Lee A. Hebert(8), Jai Radhakrishnan(8), Vladimı́r Tesař(7), Richard Lafayette(7), Richard J. Glassock(6), Heather N. Reich(6), Sanjeev Sethi(6), Sydney Tang(6), Gerald B. Appel(6), Ana Malvar(6), Sharon G. Adler(5), Keisha L. Gibson(5), Juan M. Mejía‐Vilet(5), Richard Furie(5), Samir V. Parikh(5), Haikady N. Nagaraja(5), Charles E. Alpers(5)